<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519401</url>
  </required_header>
  <id_info>
    <org_study_id>000102010</org_study_id>
    <nct_id>NCT01519401</nct_id>
  </id_info>
  <brief_title>Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.</brief_title>
  <official_title>Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the
      metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).

      The objective of this study is to compare the effects of a long term administration of two EP
      combinations, containing the same progestin (3 mg drospirenone) and a different dose of
      ethinyl-estradiol (EE) (20 vs 30 μg ) on the clinical and endocrine-metabolic parameters in
      normal weight PCOS women. The investigators enrolled 30 patients, randomly allocated to group
      A (20 µg EE - 3 mg DRSP) and 15 to group B (30 µg EE - 3 mg DRSP). Hirsutism score
      evaluation, hormonal assays, oral glucose tolerance test, euglycaemic hyperinsulinaemic clamp
      and lipid profile were performed at baseline and after 6 and 12 months of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effects of two EP combinations on endocrine-metabolic parameters in normal weight PCOS women</measure>
    <time_frame>twelve months</time_frame>
    <description>hormonal assays, oral glucose tolerance test, euglycaemic hyperinsulinaemic clamp and lipid profile</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Estro-progestin Drugs</condition>
  <arm_group>
    <arm_group_label>3 mg drospirenone and 20 µg ethinyl-estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg drospirenone and 30 µg ethinyl-estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg drospirenone and 20 µg ethinyl-estradiol</intervention_name>
    <arm_group_label>3 mg drospirenone and 20 µg ethinyl-estradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg drospirenone and 30 µg ethinyl-estradiol</intervention_name>
    <arm_group_label>3 mg drospirenone and 30 µg ethinyl-estradiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal weight women with Polycystic ovary syndrome, diagnosed in accordance with
             Rotterdam Consensus Conference Criteria 2003.

        Exclusion Criteria:

          -  pregnancy

          -  past history of cardiovascular disease, diabetes mellitus (or impaired glucose
             tolerance as determined by a standard 75 g oral glucose tolerance test), hypertension

          -  significant liver or renal impairment

          -  other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for
             the clinical signs)

          -  neoplasms

          -  unstable mental illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Maurizio Guido</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>drospirenone ethinylestradiol</keyword>
  <keyword>androgens</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

